About

Editor's emulsion 17th May 2018

Editor's emulsion 17th May 2018


Warm Greetings on yet another edition of The Prescription!

 

 

Reporting the side effects of a drug could help determine if the medicine should stay or be pulled off shelves. A medicine labelled safe for clinical use after trials could still be found to be dangerous. This data is important for a drug to be termed safe for consumption. Unfortunately, India has been poorly reporting adverse drug reactions in the last few years as Pharmacovigilance existed only on paper back then. Things seem to be improving but there’s still lots to achieve. Read our PSM India Capsules to know the reasons behind India’s poor track record in reporting ADRs.

 

 

While the Union government has approved the roll-out of the WHO-recommended new triple-drug therapy (TDT) in four select districts, including one in Maharashtra, to eliminate lymphatic filariasis (LF) from the country, the Commerce Ministry exempts pharma companies from barcoding for exports for six months; read this and more about red band warnings to be appearing on all listed drugs from now on under Drug Laws and Policy Injections.

 

 

Progress is being made not only on nabbing counterfeiters but suspending licences of Pharma firms after surprise inspections. While Maharashtra FDA raids reveal spurious abortion medicines, kits being sold illegally and drugs worth 10 crore rupees being seized by the DRI from the foreign post office, the Food and Drug Administration (FDA) has cancelled licences of four pharmaceutical companies in Pune division after they were found violating norms. Licences of 23 other errant manufacturing companies were also suspended. Catch up with all these latest happenings in our Pharma Injections and Drug Dopes section.

 

 

National Injections and Global injections of this issue of The Prescription covers some interesting news on the Delhi government likely to be putting a cap on hospital profits, CDSCO increasing WHO GMP certificate to three years for ease of doing business, HC asking government to set up panel to check adverse drug reactions and ‘Black Box’ calling for medical devices to detect errors.

 

 

We constantly endeavour not only to collate important information from the health and medicine world but also to create a connect with consumers all over. We welcome articles and write ups from our readers and are glad to feature them under the section titled Subscriber’s Symptoms. This issue features a contribution by an active pharmacist, Mr.Deepak Barai on a delicate subject of medical negligence. It is a must read.

 

 

Do not hesitate to mail your comments on this newsletter to help us improve further. We appreciate your support and trust in us and are happy to have you as our loyal reader.

Feedback is what keeps us going. Should you have any query or question, please feel free to get in touch with us. Write to me on pooja@safemedicinesindia.in

 

Stay Healthy. Stay Safe.

 

Pooja Mishra Khaitan

Editor-in-Chief,

The Prescription